Revolution Medicine has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...
Patients with RAS G12D non-small cell lung cancer remain a population with a significant unmet medical need for targeted therapeutic options,” said Jonathan Riess M.D., medical director of thoracic ...
Early results presented at a cancer research conference showed tumor shrinkage and slowed disease progression in patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results